Next-level efficiency and sustainability: SCHOTT Pharma unveils innovative nest design for ready-to-use cartridges

EQS-News: SCHOTT Pharma AG & Co. KGaA

/ Key word(s): Market Launch

Next-level efficiency and sustainability: SCHOTT Pharma unveils innovative nest design for ready-to-use cartridges

04.12.2024 / 11:00 CET/CEST

The issuer is solely responsible for the content of this announcement.

Next-level efficiency and sustainability: SCHOTT Pharma unveils innovative nest design for ready-to-use cartridges

  • New diamond-shaped nest design for ready-to-use (RTU) cartridges boosts efficiency in pharmaceutical filling processes by up to 67% and significantly reduces CO2 emissions by close to 25% in the supply chain for 1.5 ml RTU cartridges.
  • Depending on the specifications of the cartridges, the new nest increases packing density by up to 60% while improving stability and maintaining the same external nest dimensions.
  • With the new nest, pharma companies benefit from faster fill-and-finish operations of critical medications, including GLP-1, insulin, and hormone therapies.

 

SCHOTT Pharma, a pioneer in drug containment and delivery solutions, announces the launch of its groundbreaking nest design for ready-to-use (RTU) cartridges known as cartriQ®. The new nest retains its external dimensions, while the cartridges are fixated in diamond-shaped holes instead of round ones. This optimized configuration significantly increases the packing density by up to 60% while improving stability, which is crucial as the cartridges remain in the nest during the entire filling process. “With this revolutionary product, we are proactively addressing one of the key factors in reducing costs for pharmaceutical companies and reorganizing their value chain. Our new nest for RTU cartridges not only enhances operational efficiency by up to 67% when using 1.5 ml cartridges, but also significantly contributes to sustainability efforts in the industry,” said Andreas Reisse, CEO of SCHOTT Pharma. “We have received positive feedback from our customers so far,” he adds, citing the case of a Big Pharma company where the new nest for 3 ml RTU cartridges has also been optimized for high packaging density using the same approach. In the long term, this change can save a pharma company a considerable amount of CO2 per year.

SCHOTT Pharma’s new nest is available For Human Use (FHU) and is manufactured at the company’s production site in St. Gallen, Switzerland with the outlook of further sites adopting it in the future. It is a complete solution that enhances the efficient filling of high-quality drugs, such as GLP-1, insulin, and hormone therapies. Depending on the requirements of the drug and therefore the format of the cartridge, SCHOTT Pharma managed to fit as many as 160 RTU cartridges in one nest when using the 1.5 ml cartriQ® format while ensuring highest quality and stability.

Driving high-value solutions to meet customer needs

The complete platform of cartriQ® sterile cartridges ranges from small to large filling volumes of 1.5 ml to 20 ml. As an RTU solution, the cartridges are crimped, pre-washed, depyrogenated, siliconized, and steam sterilized. This preparation enables CDMOs and pharma companies to commence the filling process immediately, bypassing the need to manage these preliminary steps themselves. As part of SCHOTT Pharma’s high-value solutions (HVS) portfolio, these cartridges and the new nest exemplify the company’s commitment as a reliable partner to the pharma industry, providing premium, innovative solutions that meet the customers’ needs.

 

About SCHOTT Pharma

Human health matters. That is why SCHOTT Pharma designs solutions grounded in science to ensure that medications are safe and easy to use for people around the world. The portfolio comprises drug containment solutions and delivery systems for injectable drugs ranging from prefillable glass and polymer syringes to cartridges, vials, and ampoules. Every day, a team of over 4,600 people from over 60 nations works at SCHOTT Pharma to contribute to global healthcare. The company is represented in all main pharmaceutical hubs with 16 manufacturing sites in Europe, North and South America, and Asia. With over 1,000 patents and technologies developed in-house and a state-of-the-art R&D center in Switzerland, the company is focused on developing innovations for the future. SCHOTT Pharma AG & Co. KGaA is headquartered in Mainz, Germany and listed on the Frankfurt Stock Exchange as part of the MDAX. It is part of SCHOTT AG, which is owned by the Carl Zeiss Foundation. In light of this spirit, SCHOTT Pharma is committed to sustainable development for society and the environment and has the strategic goal of becoming climate-neutral by 2030. Currently, SCHOTT Pharma has over 1,800 customers including the top 30 leading pharma manufacturers for injectable drugs and generated revenue of EUR 899 million in the fiscal year 2023. Further information at www.schott-pharma.com.

 

Press contact:

Joana Kornblum
Media Relations
Tel.: +49 151/29223552 
E-Mail: joana.kornblum@schott.com   
 

Jasko Terzic, CFA 
Senior Manager Investor Relations 
E-Mail: ir.pharma@schott.com  


04.12.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


show this

aap Implantate AG: resolves to convene an Annual General Meeting to elect a new auditor

aap Implantate AG / Key word(s): AGM/EGM

aap Implantate AG: resolves to convene an Annual General Meeting to elect a new auditor

03-Dec-2024 / 20:22 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.


The Management Board of aap Implantate AG (the “Company”) today resolved to convene a General Meeting to resolve on the proposal of the Supervisory Board on the appointment of a new auditor for the financial year 2024. The background to the Supervisory Board’s proposal is that the auditor elected by the Annual General Meeting on August 15, 2024 for the financial year 2024 informed the Company today that he will not be available for the audit of the annual and consolidated financial statements of the Company for the financial year 2024 and therefore no mandate relationship for the audit of the annual and consolidated financial statements for the financial year 2024 will be established between the Company and the auditor elected by the Annual General Meeting.

The company assumes that the Audit Committee will nominate a new auditor at its meeting on Thursday, December 5, 2024, after completion of the ongoing simplified selection procedure in accordance with Art. 16 EU Regulation 537/2014, which the Supervisory Board will propose to the company’s shareholders for election at the Annual General Meeting, which is scheduled to take place on January 15, 2025.

This Annual General Meeting will also deal with other agenda items not discussed at the Annual General Meeting on August 15, 2024.

 

——————————————————————————————————————————————-

aap Implantate AG (ISIN DE0005066609) – General Standard/Regulated Market – All German stock exchanges –

About aap Implantate AG

aap Implantate AG is a globally active medical technology company based in Berlin, Germany. The company develops, produces and markets products for traumatology. In addition to the innovative LOQTEQ® anatomical plate system, the IP-protected portfolio includes a wide range of cannulated screws. In addition, aap Implantate AG has an innovation pipeline with promising development projects such as antibacterial silver coating technology and magnesium-based implants. These technologies address critical problems in traumatology that have not yet been adequately solved. In Germany, aap Implantate AG sells its products directly to hospitals, purchasing groups and group clinics, while internationally it primarily uses a broad network of distributors in around 25 countries. In the USA, the company relies on a hybrid sales strategy through its subsidiary aap Implants Inc. Sales are conducted both through distribution agents and through partnerships with global orthopedic companies. The aap Implantate AG share is listed in the General Standard of the Frankfurt Stock Exchange (XETRA: AAQ.DE). For further information, please visit our website at www.aap.de.

 

 

Forward-looking statements

This release may contain forward-looking statements that are based on the current expectations, assumptions and forecasts of the Executive Board and information currently available to it. The forward-looking statements are not to be understood as guarantees of the future developments and results mentioned therein. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual results, financial situation, development or performance of the company and the estimates given here. These factors include those that aap has described in published reports. Forward-looking statements therefore speak only as of the date on which they are made. We assume no obligation to update the forward-looking statements made in this release or to adapt them to future events or developments.

 

If you have any questions, please contact: aap Implantate AG; Rubino Di Girolamo; Chairman of the Management Board/ CEO; Lorenzweg 5; 12099 Berlin

Phone: +49 (0)30 75019 – 141; Fax: +49 (0)30 75019 – 290; Email: r.digirolamo@aap.de

End of Inside Information


03-Dec-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


show this

Eckert & Ziegler: Changes in the Executive Board and Supervisory Board

EQS-News: Eckert & Ziegler SE

/ Key word(s): Personnel

Eckert & Ziegler: Changes in the Executive Board and Supervisory Board

03.12.2024 / 14:29 CET/CEST

The issuer is solely responsible for the content of this announcement.

Berlin, 3 December 2024. The Supervisory Board of Eckert & Ziegler SE has appointed Dr. Gunnar Mann (57) as a new member of the Executive Board, effective 1 January 2025. He will assume operational responsibility for the Medical segment.

Dr. Mann who holds a doctorate in physics, joined Eckert & Ziegler in 1998 and initially started as head of development. He then served as managing director of various subsidiaries of Eckert & Ziegler SE and was appointed to the Group Executive Committee in 2011. Dr. Mann has proven expertise in the areas of radiation physics, process management and implementation of investment projects.

Jutta Ludwig, whose contract as a member of the Executive Board expires as planned on December 31, 2024 will join the Supervisory Board as a delegated member on January 1, 2025. Frank Perschmann will leave the Supervisory Board of Eckert & Ziegler SE at the end of the year.

“Dr. Mann knows Eckert & Ziegler like only few others and brings exactly the experience and expertise needed to expand production capacity in the growing medical segment and to set up facilities for new products,” explains Dr. Andreas Eckert, Chairman of the Supervisory Board of Eckert & Ziegler SE. “On behalf of the Supervisory Board, I would like to thank Mrs. Ludwig for her contribution in strengthening our position in China and I am pleased that her expertise will remain with the company. I would also like to express my thanks to Mr. Perschmann for his many years of work on the Supervisory Board and for his valuable input in the strategic development of the Group.”

About Eckert & Ziegler.
Eckert & Ziegler SE with more than 1.000 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.

Your contact:
Eckert & Ziegler SE, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com 

 


03.12.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


show this

Viromed Medical AG is expanding its Management Board – Christian Strauch has been appointed as a new member of the Management Board

EQS-News: Viromed Medical AG

/ Key word(s): Personnel

Viromed Medical AG is expanding its Management Board – Christian Strauch has been appointed as a new member of the Management Board

03.12.2024 / 15:00 CET/CEST

The issuer is solely responsible for the content of this announcement.

Viromed Medical AG is expanding its Management Board – Christian Strauch has been appointed as a new member of the Management Board

Pinneberg, 3 December 2024 – The Supervisory Board of Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65; “Viromed”) has appointed Mr. Christian Strauch as a new member of the company’s Management Board with effect from 1 January 2025. The previous sole member of the Management Board, Uwe Perbandt, has been appointed Chairman of the Management Board.

“Viromed Medical AG is facing major challenges in the further research, application and global marketing of cold plasma technology. In order to meet these challenges efficiently and successfully, we need to spread the workload across a larger team. In Christian Strauch, we have found an outstanding and internationally experienced expert who, with his extensive know-how, can make a significant contribution to the success of the company,” explained Dr. Jan Delphendahl, Chairman of the Supervisory Board of Viromed Medical AG.

Christian Strauch has a degree in business administration (“Diplom-Kaufmann”) and has many years of experience and a proven track record in building and expanding companies within the healthcare sector. He also has an international network of contacts with decision-makers in the development, manufacturing and distribution of healthcare products. His professional career includes, among other things, more than ten years as a member of the management board of the mail-order pharmacy apo-rot, where he ultimately held the position of managing director. He was also the founder of Linsentaxi GmbH and Pauls Praxis GmbH, as well as the founder and managing partner of pharmedix GmbH. Most recently, he was managing partner of Vameda GmbH, a holding company for corporate investments in the healthcare sector.

Uwe Perbandt, former sole member of the Management Board of Viromed Medical AG, added: “I am very much looking forward to working with Christian Strauch in the future. With his experience and contacts, he will actively support and assist me in the next steps of Viromed’s growth. This will enable me to focus more on my core competencies and together we can lead the company to success.”

About Viromed Medical AG:

Viromed Medical AG specializes in the development, manufacture and distribution of medical products. The operating business of the company, which has been listed on the stock exchange since October 2022, focuses on the distribution of innovative cold plasma technology for medical applications via its wholly owned subsidiary Viromed Medical GmbH. Viromed can draw on a broad customer base in the DACH region. Viromed Medical AG is pursuing the goal of further advancing the use of CAP in medicine in the coming years and realizing the corresponding growth potential.

 

Contact Viromed Medical AG

Uwe Perbandt
CEO
Flensburger Straße 18
25421 Pinneberg
E-Mail: kontakt@viromed-medical.de
www.viromed-medical-ag.de

 


03.12.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


show this

Viromed Medical AG plans to acquire all shares in pharmedix GmbH by means of a capital increase against a contribution in kind, excluding subscription rights.

Viromed Medical AG / Key word(s): Mergers & Acquisitions

Viromed Medical AG plans to acquire all shares in pharmedix GmbH by means of a capital increase against a contribution in kind, excluding subscription rights.

03-Dec-2024 / 13:53 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.


Viromed Medical AG plans to acquire all shares in pharmedix GmbH by means of a capital increase against a contribution in kind, excluding subscription rights.

Pinneberg, 3 December 2024 – Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65; “Viromed”; the “Company”) plans to acquire all shares in pharmedix GmbH, Hamburg, and thus to expand its portfolio strongly. To this end, the Company signed a corresponding agreement with the shareholders of pharmedix GmbH today.

pharmedix GmbH specializes in the development, marketing and distribution of products and brands in the healthcare sector. Through its international network, it has access to the latest technologies and processes in microbiology and pharmaceutics, as well as to the highest quality raw materials and state-of-the-art production facilities. pharmedix’s portfolio includes medical devices and medical cosmetics under the N1® and ORTHOCOMPLEX® brands. The company was founded in 2021. For the 2024 financial year, a nearly balanced operating result is already expected with revenues of more than EUR 4.0 million. For 2025, a revenue growth of 35% to approximately EUR 5.5 million and a positive operating result are planned. The target for the period to 2029 is to achieve average annual revenue growth of 25% and an operating margin of between 15% and 20%.

The closing of the acquisition is expected to take effect on 1 January 2025. The transaction is subject to the final results of the due diligence. The purchase price for the complete acquisition of the shares in pharmedix GmbH is expected to be a maximum of EUR 2.0 million. The purchase price payment is to be made exclusively by granting new shares in the company, making partial use of the Authorized Capital 2022, as part of a capital increase against contributions in kind, excluding shareholders’ subscription rights.

 

Contact Viromed Medical AG

Uwe Perbandt
CEO
Flensburger Straße 18
25421 Pinneberg
E-Mail: kontakt@viromed-medical.de
www.viromed-medical-ag.de

End of Inside Information


03-Dec-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


show this

Gerresheimer builds new production capacities for glass syringes at Skopje site 

EQS-News: Gerresheimer AG

/ Key word(s): Expansion

Gerresheimer builds new production capacities for glass syringes at Skopje site 

02.12.2024 / 13:30 CET/CEST

The issuer is solely responsible for the content of this announcement.

Gerresheimer builds new production capacities for glass syringes at Skopje site 

  • Expansion of the site in the Republic of North Macedonia with a new production hall for glass syringes
  • Total investment volume of over EUR 100 million
  • Around 250 new jobs for skilled workers from the region
  • Ramp-up of syringe production starting by the end of 2024

Düsseldorf/Skopje, December 2, 2024. Gerresheimer, an innovative system and solution provider and a global partner for the pharma, biotech and cosmetics industries, is expanding its production capacity in Skopje, North Macedonia, with a new production hall for syringes. Since 2019, Gerresheimer has been producing drug delivery systems, diagnostic and medical products made of plastic on around 14,600 m² at this site. The new factory hall adds around 7,600 m² of production space for glass syringes. The company is investing over EUR 100 million in the construction and equipment of the new building. The expansion of the site will double the number of employees in Skopje from around 250 to 500 over the next three to five years. The new production hall in Skopje is currently one of the key projects in the global capacity expansion for drug delivery systems and syringes for long-term customer contracts.

 “Combining production capacities for plastic and glass at one location for the efficient production of integrated solutions for the pharma industry is a further step in the implementation of our corporate strategy formula g,” explains Dietmar Siemssen, CEO of Gerresheimer AG. “As a systems and solutions provider, our customers receive individually tailored, fully integrated solutions. In the future, for example, we will also supply ready-to-fill syringe systems from Skopje.”

New syringe production hall for the highest demands

The new production hall is specifically designed for the manufacture of syringes and other primary packaging made of tubular glass. The total area, including Good Manufacturing Practice (GMP) Class C and D clean rooms, covers around 7,600 square meters – roughly the size of a soccer field. The new hall provides space for the precision glass forming lines developed and manufactured by Gerresheimer itself, as well as specific assembly and ready-to-fill lines.

Glass and plastics production with growth reserve at one location

Since 2019, Gerresheimer has been producing drug delivery systems as well as diagnostic and medical products and components made of plastic on around 14,600 m² in Skopje, including ISO class 7, 8 and 9 clean rooms. This also includes syringe accessories such as the Gerresheimer Gx TELC syringe closure system and the Gx InnoSafe safety system, which protects against accidental needlestick injuries. 

One advantage of the plant in Skopje, with its 7,600 m² extension, is the combination of production capacities for pharmaceutical plastic and glass products at one location. This enables efficient production of integrated solutions with optimized logistics. For example, customers can obtain fully assembled ready-to-fill syringe systems in a wide variety of configurations from Skopje. The site in Skopje also offers growth potential. 100,000 m² of additional space is available on the site for future expansion.     

Quality assurance with state-of-the-art technology

Gerresheimer uses state-of-the-art inspection systems for quality assurance as part of its certified quality management system, including, for example, the Gx G3 inspection system with high-speed camera technology and AI-based image processing developed in-house by Gerresheimer for the syringe production. In addition, the plant in Skopje has two in-house laboratories with high precision measurement technology and laboratory equipment for optical, mechanical, chemical and microbiological testing.

Very good infrastructure and local specialists

Gerresheimer’s Skopje site is located in a well-connected industrial area close to the international airport of the North Macedonian capital. Larger Mediterranean ports in Greece and Albania are each around 250 km away. The country has a well-trained workforce. Around a quarter of Gerresheimer’s workforce at the site was trained by Gerresheimer experts in Germany. In addition, Gerresheimer cooperates with the University of Skopje in order to recruit qualified young talents. 

Ramp-up of syringe production in Skopje by the end of 2024
The first syringe production lines will ramp up in Skopje shortly, with more to be added in the course of 2025. This means that Gerresheimer is currently concentrating syringe production at its sites in Bünde (Germany), Querétaro (Mexico) and Skopje (Republic of North Macedonia).

 

About Gerresheimer 
Gerresheimer is an innovative systems and solutions provider and a global partner for the pharma, biotech and cosmetic industries. The company offers a comprehensive portfolio of pharmaceutical containment solutions, drug delivery systems and medical devices as well as solutions for the health industry. The product range includes digital solutions for therapy support, medication pumps, syringes, pens, auto-injectors and inhalers as well as vials, ampoules, tablet containers, dropper bottles, other bottles and more. Gerresheimer ensures the safe delivery and reliable administration of drugs to the patient. With 35 production sites in 16 countries in Europe, America and Asia, Gerresheimer has a global presence and produces locally for regional markets. With around 12,000 employees, the company generated revenues of around €2bn in 2023. Gerresheimer AG is listed in the MDAX on the Frankfurt Stock Exchange (ISIN: DE000A0LD6E6).  
www.gerresheimer.com 

Contact Gerresheimer AG

Media  
Jutta Lorberg
Head of Corporate Communication
T +49 211 6181 264

jutta.lorberg@gerresheimer.com
Marion Stolzenwald
Senior Manager Corporate Communication
T +49 172 2424185

marion.stolzenwald@gerresheimer.com
Investor Relations  
Guido Pickert
Vice President Investor Relations

T +49 152 900 14145
gerresheimer.ir@gerresheimer.com

 
Thomas Rosenke
Senior Manager Investor Relations
T: +49 211 6181-187
gerresheimer.ir@gerresheimer.com


02.12.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


show this

Uni-Bio Science Secures Approval for Recombinant Collagen Class II Medical Device and Launches 肌顏態®: Pioneering Entry into the High-Growth Medical Aesthetics Market

EQS Newswire / 02/12/2024 / 18:14 UTC+8

         2nd December 2024 –Uni-Bio Science Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce two significant milestones that demonstrate the Group’s continued growth and innovation in the field of medical aesthetics and dermatological solutions.

The Groups strategic cooperation product with Chongqing Minji Medical Device Co., Ltd., recombinant collagen dressing, has successfully received Class II medical device approval, with the approval number “渝械注准 20242140377″. At the same time, the Groups self-developed medical aesthetics product, 肌顏態®, was successfully launched, marked by a grand event held in Wuhan. The launch brought together industry experts, key opinion leaders,

image1

Photo: group photo of the launch of 肌顏態®

media representatives, and other professionals to witness the Group’s entry into the rapidly growing medical aesthetics market, valued at hundreds of billions of RMB. This milestone signifies a bold new chapter for the Group as it continues to expand its presence in this high-potential sector.

Collagen, which is central to the newly approved recombinant collagen dressing, is the most abundant protein in the human body, comprising 25–35% of total protein content. It forms a network of elastic fibers that support the skin’s structure, maintain elasticity, and lock in moisture. However, collagen production decreases by approximately 1% annually after maturity (around age 21), leading to a loss of skin firmness and elasticity. Collagen-based products have a wide range of applications, including moisturizing, maintaining the skin barrier, and addressing signs of aging. In addition to dressing, microneedles for collagen are also being developed.

The launch of 肌顏態®, developed based on proprietary patents of SkbrellaFN (Recombinant Human Fibronectin), marks another key milestone in the Groups efforts to expand its portfolio. 肌顏態® is designed to provide safe, effective solutions for improving skin quality and repair, making it ideal for treating damaged skin, acne-prone skin, and for post-medical procedure care. Fibronectin, a multifunctional extracellular matrix glycoprotein, plays a vital role in cell migration, adhesion, proliferation, hemostasis, and tissue repair. It is worth mentioning that the Group is advancing the development of its fibronectin-based medical device.

image2

Photo left:肌顏態® Fibronectin Repair Solution; Photo right:肌顏態® Fibronectin Serum

The debut of肌顏態® has attracted high recognition and attention from many dermatologists and medical aesthetics practitioners. At the launch, experts and scholars conducted professional academic exchanges and case sharing on the effects and clinical use of fibronectin from different perspectives “肌顏態®, a product designed for use throughout the entire cycle of preoperative and post-medical procedures, demonstrates significant effectiveness, particularly for patients with anesthetic allergies. It enables rapid skin repair and reduces redness efficiently. “

image3
Photo: Dermatology clinical practice sharing by Professor Yang Bin, President of Guangdong Dermatology Hospital, Southern Medical University
image4

Photo: 肌顏態® use case sharing by Professor Shi Ge, Director of the Department of Plastic Surgery of the Sixth Affiliated Hospital of Sun Yat-sen University

Mr. Frank Zhao, CEO of Uni-Bio Science Group, also said: “The Group will leverage its professional expertise in dermatology, nearly three decades robust clinical data from GeneTime , and its established sales network, adhering to the rigorous R&D standards of pharmaceutical companies, to build a diversified product portfolio across biological drugs, medical devices, and medical aesthetics, ultimately providing safer and more effective full-cycle skincare solutions for patients.”

image5

Photo left: Mr. Frank Zhao, CEO of Uni-Bio Science Group delivered opening speech for the launch of 肌顏態®; Photo right: Dr. Yu Shan, Deputy Director of R&D and Project of Uni-Bio Science Group, introduction of 肌顏態®

The Group is well-positioned to capitalize on the growing opportunities in the market. Industry forecasts indicate that the medical aesthetic market is set to sustain a CAGR growth of 10% to 15% between 2024 and 2027, and is expected to exceed RMB 600 billion in 2030. The approval of collagen medical devices and the launch of 肌顏態® herald a new journey for the Group in the field of skin care.

image6

Photo: Mr. Kingsley Leung, Chairman of Uni-Bio Science Group, success entered in partnerships with various renowned medical aesthetics clinic chain and distributors

These achievements reflect the Group’s strong commitment to innovation, strategic execution, and value creation. As the Group continues to execute its strategic vision, it remains focused on its goal of becoming China’s leading expert in dermatology, leveraging innovation, clinical expertise, and market insight to drive sustainable growth and long-term success.

 

 

End

02/12/2024 Dissemination of a Financial Press Release, transmitted by EQS News.
The issuer is solely responsible for the content of this announcement.

Media archive at www.todayir.com

show this

Eckert & Ziegler Begins Production of Actinium-225, Paving the Way for GMP-Grade Supply

EQS-News: Eckert & Ziegler SE

/ Key word(s): Product Launch

Eckert & Ziegler Begins Production of Actinium-225, Paving the Way for GMP-Grade Supply

02.12.2024 / 09:00 CET/CEST

The issuer is solely responsible for the content of this announcement.

Berlin, 02 December 2024. Eckert & Ziegler Radiopharma GmbH (Eckert & Ziegler) today celebrates the successful start of Actinium-225 (Ac-225) production, addressing the global shortage of this critical radionuclide. This milestone marks a major success of the common project with the Nuclear Physics Institute of the Czech Academy of Sciences (ÚJF). The test production demonstrated that the choice of technology was appropriate to achieve the expected parameters of the product.

In parallel with production, Eckert & Ziegler has commenced the validation process to produce GMP-grade Ac-225, crucial for clinical and commercial use. It is expected to become available in the first half of 2025, unlocking new opportunities for pharmaceutical companies developing alpha-emitting radiopharmaceuticals.

The production facility employs innovative cyclotron-based methods to generate Ac-225 from Radium-226, marking a pivotal advancement in isotope production. “This milestone underscores our commitment to advancing cancer treatment through the reliable supply of radioisotopes,” said Dr. Lutz Helmke, Managing Director of Eckert & Ziegler Radiopharma GmbH. “The commencement of Ac-225 production not only addresses the current shortage but also fortifies Eckert & Ziegler’s position as a key player in the future of radioligand therapy.”

The successful start of Ac-225 production is a direct result of the close collaboration between Eckert & Ziegler and the ÚJF. Drawing on decades of expertise in nuclear research and radiopharmaceutical development, ÚJF has played a crucial role in designing and optimizing this production pathway for Ac-225. Incorporating custom-engineered solutions by Isotope Technologies Dresden GmbH, Eckert & Ziegler’s hot cell division, the production process is designed to be efficient and sustainable.

The start of production positions Eckert & Ziegler at the forefront of the radiopharmaceutical industry’s transformation, offering a reliable and scalable source of Ac-225 for clinical development and commercial manufacturing.

About Eckert & Ziegler SE
Eckert & Ziegler SE, with more than 1,000 employees, is a leading specialist in isotope-related components for nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler SE shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.

Contact
Eckert & Ziegler SE
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Jan Schöpflin, Marketing / Karolin Riehle, Investor Relations
jan.schoepflin@ezag.de / karolin.riehle@ezag.de
Tel.: +49 (0) 30 / 94 10 84-138; www.ezag.com


02.12.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


show this

Mainz Biomed Announces Stock Split

Issuer: Mainz BioMed N.V.

/ Key word(s): Miscellaneous

29.11.2024 / 14:45 CET/CEST

The issuer is solely responsible for the content of this announcement.

Mainz Biomed Announces Stock Split

BERKELEY, US and MAINZ, Germany – November 29, 2024Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced a 1-for-40 reverse stock split of its issued and outstanding shares.  The reverse stock split was authorized by the Board of Directors of the Company pursuant to shareholder approval granted at its Extraordinary Shareholders Meeting on November 20, 2024.

The reverse stock split is expected to become effective on December 3, 2024 (the “Effective Date”), and the Company’s ordinary shares are expected to begin trading on the split-adjusted basis on the Nasdaq under the Company’s existing trading symbol “MYNZ” at market open on December 3, 2024, upon Nasdaq’s approval. The new CUSIP number for the Company’s ordinary shares following the reverse stock split will be N5436L119.

The reverse stock split is intended to increase the market price per share of its common stock to comply with the continued listing standards of the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) and to make investments in the Company more attractive to investors by increasing the trading price of the Company’s ordinary shares on such market.

Information for Stockholders

On the Effective Date, every 40 issued and outstanding ordinary shares of the Company will be converted automatically into one share of the Company’s ordinary shares without any change in the par value per share. Once effective, the reverse stock split will reduce the number of ordinary shares issued and outstanding from approximately 80.1 million shares to approximately 2.0 million.

Immediately after the reverse stock split, each stockholder’s percentage ownership interest in the Company and proportional voting power will remain unchanged, except for minor changes and adjustments that will result from the treatment of fractional shares. The Company will not issue fractional shares but will pay cash in lieu of fractional shares.  The rights and privileges of the holders of ordinary shares of the Company will be substantially unaffected by the reverse stock split.

Shareholders who hold their shares in brokerage accounts or in “street name” will have their positions automatically adjusted to reflect the reverse stock split, subject to each broker’s particular processes, and will not be required to take any action in connection with the reverse stock split.

Registered shareholders holding pre-split shares of the Company’s ordinary shares electronically in book-entry form are not required to take any action to receive post-split shares. Those shareholders holding shares of the Company’s ordinary shares in certificate form will receive a transmittal letter from our transfer agent, Transhare Corporation, with instructions as soon as practicable after the Effective Date.

Nasdaq Capital Market Compliance

Mainz Biomed’s securities are currently listed on Nasdaq. In May 2024, the Company received written notice (the “Notice”) from the Listing Qualifications Department of Nasdaq notifying that, based on the closing bid price of Mainz Biomed’s ordinary shares for the last 30 consecutive trading days, the Company no longer complied with the minimum bid price requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”), and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the Minimum Bid Price Requirement exists if the deficiency continues for a period of 30 consecutive trading days. Pursuant to the Nasdaq Listing Rules, Mainz Biomed were provided with an initial compliance period of 180 calendar days to regain compliance with the Minimum Bid Price Requirement. To regain compliance, the closing bid price of ordinary shares has to be at least $1.00 per share for a minimum of 10 consecutive trading days prior to November 25, 2024. Additionally, the Company no longer meets the minimum $2,500,000 minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market set forth in Listing Rule 5550(b)(1).

On November 27, 2024, Mainz Biomed received a staff determination letter (the “Determination Letter”) from Nasdaq stating that the Company had not regained compliance with the Minimum Bid Price Requirement by November 25, 2024, and is not eligible for a second 180-day period The Determination Letter has no immediate effect on the listing of Mainz Biomed’s ordinary shares on the Nasdaq Capital Market. The Company intends to shortly file a hearing request that automatically stays any suspension or delisting action pending the hearing and the expiration of any additional extension period granted by the Nasdaq Hearing Panel (the “Panel”) following the hearing.  In that regard, pursuant to the Nasdaq Listing Rules, the Panel has the authority to grant an extension not to exceed 180 days from the date of the Determination Letter.

Please visit Mainz Biomed’s official website for investors at mainzbiomed.com/investors/ for more information

Please follow us to stay up to date:
LinkedIn
X (Previously Twitter)
Facebook

About Mainz Biomed NV
Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert®, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer. ColoAlert® is marketed across Europe. The Company is currently running a pivotal FDA clinical study for US regulatory approval. Mainz Biomed’s product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. To learn more, visit mainzbiomed.com or follow us on LinkedIn, Twitter and Facebook.

For media inquiries

MC Services AG
Anne Hennecke/Caroline Bergmann
+49 211 529252 20
mainzbiomed@mc-services.eu

For investor inquiries, please contact info@mainzbiomed.com

Forward-Looking Statements

Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company’s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the “SEC”) by the Company. Additional information concerning these and other factors that may impact the Company’s expectations and projections can be found in its initial filings with the SEC, including its annual report on Form 20-F filed on April 9, 2024. The Company’s SEC filings are available publicly on the SEC’s website at www.sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.


Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


show this

Viromed Medical AG will not acquire ActivCell Group AG and is focusing on another strategic option with greater added value

Viromed Medical AG / Key word(s): Mergers & Acquisitions

Viromed Medical AG will not acquire ActivCell Group AG and is focusing on another strategic option with greater added value

29-Nov-2024 / 15:06 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.


Viromed Medical AG will not acquire ActivCell Group AG and is focusing on another strategic option with greater added value

Pinneberg, 29 November 2024 – Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65; “Viromed”; the “Company”) has terminated negotiations for the planned acquisition of all shares in ActivCell Group AG, Switzerland, and will not pursue this opportunity further.

On 17 September, Viromed had originally announced its intention to acquire 100% of ActivCell Group AG. The purchase price for this was to be in the mid-single-digit million euro range and was to be paid exclusively by granting new shares in the company, making partial use of the authorized capital 2022, in the context of a capital increase against contributions in kind, excluding shareholders’ subscription rights.

In the course of further negotiations, Viromed’s management board has come to the conclusion that the added value of the proposed transaction in relation to the purchase price does not meet the company’s expectations. Therefore, the negotiations will not be continued.

Viromed Medical AG already has its own device, ViroCAP, which is by far the most advanced and innovative model in this field. The company has already made significant progress in the MDR 2a approval process with this device and is now focusing on bringing it to market on a broad scale.

 

Contact Viromed Medical AG

Uwe Perbandt
CEO
Flensburger Strasse 18
25421 Pinneberg
Germany
Email: kontakt@viromed-medical.de
www.viromed-medical-ag.de

End of Inside Information


29-Nov-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


show this